Spoke to Hepatera Moscow today, asked about the results of Myrcludex clinical trials started in December 2012 that were supposed to end in December 2013.
The reply was that early tests showed that the drug was well tolerated and the permission was gained to increase the dose and extend the time of the therapy transferring directly to phase 2. This phase will finish in September 2014 and the results will be available by the end of the year. Next stage will be phase 3 mass trial and in case of positive results we should expect the drug in the market in 2 - 3 years from now.
